OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 42 BIOGEN 2021 YEAR IN REVIEW ADVANCING HEALTH ACCESS AND EQUITY HIGHLIGHTS of Biogen’s commitments in Product Delivery 1 We strive to ensure broad access to our therapies through both public and private healthcare systems, and both before and after a therapy’s potential regulatory approval. We run a wide range of Access Programs, as outlined in this report. Biogen also may offer financial assistance or help to secure reimbursement in public and private healthcare programs for patients who are otherwise unable to access our medications. In 2020, we initiated a pilot program in India to help expand access to SPINRAZA, including providing SPINRAZA free of charge to program participants, who were selected by an independent committee of medical experts. To date, 200 patients in India have received SPINRAZA. We are exploring the potential for future expansion within India and other countries. 2 Biogen works to overcome barriers to access for underserved patient populations through our Access Programs , Pricing Principles , and efforts to expand areas such as biosimilars, which can benefit patients and reduce costs, and access efforts such as a transportation support program for SPINRAZA patients who live hours from their site of care. For example, we have worked hard to ensure that SPINRAZA is available in 30 provinces, cities and autonomous regions across China so patients in remote areas like Gansu, Ningxia, Qinghai, Xinjiang and Inner Mongolia are able to access treatment through local hospitals. We work with regulators, clinical researchers, ethicists, physicians and Change to Patient Advocacy Groups and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. 3 Health Systems Strengthening: In 2020 we began new programs to help strengthen healthcare systems. Collaborating with Harvard University’s T.H. Chan School of Public Health’s C-CHANGE (Harvard Chan C-CHANGE) program and Americares, we instituted a first-of-its-kind program to help under-resourced healthcare clinics become more climate-resilient to help ensure continuity of access and care and to improve measurable health outcomes. The Biogen Foundation supported CareMessage, the largest patient engagement platform in the U.S., which equips at-risk communities with access to accurate healthcare information using basic text and voice messages – key to reaching people who don’t have broadband. Manufacturing/Supply Chain Capacity Building: Biogen became one of the first contributors to Massachusetts Institute of Technology’s (MIT) collaboration, The AltHost Consortium, in 2020. AltHost works to advance the speed and productivity of alternative host cell research and manufacturing, with the aim to meet escalating needs for biologic drugs through improved product quality and increased volumetric productivity with a goal of improved access and lower costs. Product Donations: Biogen runs relevant programs in a number of countries, as outlined in this report. Inclusive Business Model: We are committed to advancing DE&I via a four-part strategy. As of Dec. 31, 2021, 47.6% of director-level-and-above positions were held by women, and 26% of Biogen’s U.S. director-level- and-above positions were held by ethnic or racial minorities. In 2021, Biogen exceeded its targets for spend with minority- owned businesses. P r o d u c t D e l i v e r y STAKEHOLDER PRIORITIES Equitable access to products is primary focus Highlights overcoming any local barriers in accessing hard-to-reach markets and patient populations Includes sharing of intellectual property; strengthening of local or regional health systems; enabling of generic medication manufacturing and supply, product donations, product registration in high-burden countries, manufacturing/supply chain capacity-building, and inclusive business model 1 2 3 Access to Medicine